A complete Growth financial model for Biotech startups. Revenue model, unit economics, hiring plan, cash flow projections, and funding scenarios — structured for investor review.
Projection Horizon
3 years with LTM actuals (trailing twelve months)
Model Tabs
7 core tabs
Format
Excel + Google Sheets
EBITDA generation, free cash flow conversion, and exit multiple positioning. Growth-stage investors are sizing the return on their investment against exit scenarios.
Biotech financial models must include a probability-weighted NPV analysis. Investors value companies on risk-adjusted NPV of the program, not DCF of current revenue. Include a sensitivity table showing NPV at different PoS assumptions.
Milestone-based funding model with pre-commercial phase tracking. Map funding events (SBIR awards, partnerships, equity rounds) to clinical trial stages and regulatory milestones.
Growth stage models require GAAP financial statements as the foundation. All projections must reconcile to audited financials. Quality-of-earnings adjustments should be clearly documented with investor-friendly presentation.
Include IPO, strategic acquisition, and secondary scenarios with implied multiples based on comparable company trading and transaction comps.
A Growth Biotech financial model should cover 3 years with LTM actuals (trailing twelve months) of projections with these tabs: LTM Financial Summary, EBITDA Bridge, Free Cash Flow Model, Working Capital Analysis, Capital Structure and Debt Schedule, Scenario Analysis (exit scenarios), Comparable Company Benchmarking. EBITDA generation, free cash flow conversion, and exit multiple positioning. Growth-stage investors are sizing the return on their investment against exit scenarios.
Milestone-based funding model with pre-commercial phase tracking. Map funding events (SBIR awards, partnerships, equity rounds) to clinical trial stages and regulatory milestones. The key revenue drivers are: Collaboration and partnership revenue by agreement; Government grant and SBIR/STTR funding; Licensing milestone payments; Future royalty revenue (post-approval, risk-adjusted).
Biotech unit economics at the Growth stage should include: Cost per patient enrolled in clinical trials; Cost per milestone achieved; NPV of risk-adjusted royalty stream; Cost of goods manufactured (COGS) at commercial scale. Biotech financial models must include a probability-weighted NPV analysis. Investors value companies on risk-adjusted NPV of the program, not DCF of current revenue. Include a sensitivity table showing NPV at different PoS assumptions.
Growth stage models require GAAP financial statements as the foundation. All projections must reconcile to audited financials. Quality-of-earnings adjustments should be clearly documented with investor-friendly presentation. Start with the smallest unit of your business (one customer, one transaction, one seat) and build up from there. Every assumption should have a source or benchmark you can defend in an investor meeting.
Include IPO, strategic acquisition, and secondary scenarios with implied multiples based on comparable company trading and transaction comps.
Get the Biotech Growth financial model as a pre-built Excel and Google Sheets template. Assumptions dashboard, revenue model, unit economics, and cash flow — ready to customize.
Includes Excel file, Google Sheets version, and model documentation guide